Free Trial
→ Watch This Now (From StocksToTrade) (Ad)tc pixel
OTCMKTS:OPHLF

Ono Pharmaceutical Q3 2026 Earnings Results & Report

Ono Pharmaceutical logo
$14.90 0.00 (0.00%)
As of 11/11/2026

Ono Pharmaceutical beat analyst expectations on both earnings and revenue in its Q3 2026 results, released February 2, 2026. The company reported EPS of $0.40 versus the $0.2888 consensus estimate, while revenue of $892.70 million topped the $727.58 million estimate by $165.12 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens

Ono Pharmaceutical EPS Results

Actual EPS
$0.40
Consensus EPS
$0.2888
Beat/Miss
Beat by +$0.1112
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Ono Pharmaceutical Revenue Results

Actual Revenue
$892.70 million
Expected Revenue
$727.58 million
Beat/Miss
Beat by +$165.12 million
YoY Revenue Growth
N/A

Conference Call Resources

Ono Pharmaceutical Q3 2026 Earnings FAQ

Ono Pharmaceutical (OTCMKTS:OPHLF) reported earnings of $0.40 per share for Q3 2026, beating the consensus estimate of $0.2888. The report was announced on Monday, February 2, 2026.

Ono Pharmaceutical reported revenue of $892.70 million for Q3 2026, against a consensus estimate of $727.58 million.

Ono Pharmaceutical Earnings Headlines

Head-To-Head Survey: Ovid Therapeutics (NASDAQ:OVID) vs. Ono Pharmaceutical (OTCMKTS:OPHLF)
November 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31181236
Ono Pharmaceutical Co. Ltd. H1 Profit Rises
October 29, 2026  |  rttnews.comhttps://www.rttnews.com/3704777/ono-pharmaceutical-co-ltd-h1-profit-rises.aspx
Trump compared today's market to 1929
President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they did. Before a single vote was counted, the IMF flagged markets as increasingly exposed to a sharp correction, Ray Dalio called conditions a classic bubble, and Peter Schiff said a downturn could hit regardless of the outcome.tc pixel
November 12 at 1:00 AM  |  USA Capital Gold (Ad)
Ono Pharma Announces Results From Five Phase 2 Clinical Studies of ONO-1110, an Endocannabinoid Modulator
October 28, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261028715856/en/ono-pharma-announces-results-from-five-phase-2-clinical-studies-of-ono-1110-an-endocannabinoid-modulator/
Biohaven licenses IgG degrader portfolio to Japan’s Ono
October 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4651387-biohaven-licenses-igg-degrader-portfolio-to-japans-ono
Ono’s New Pediatric Cancer Trial Signals Steady Pipeline Progress for O.P.H.L.F Investors
October 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/onos-new-pediatric-cancer-trial-signals-steady-pipeline-progress-for-o-p-h-l-f-investors?utm_source=marketbeat.com&utm_medium=referral
See More Ono Pharmaceutical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Ono Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Ono Pharmaceutical and other key companies, straight to your email.

About Ono Pharmaceutical

Ono Pharmaceutical (OTCMKTS:OPHLF) Co., Ltd. is a Japan-based research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines. Founded in 1717 as a medicine wholesaler, the company is headquartered in Osaka.

Ono’s research and product portfolio spans areas including oncology, immunology, neurology and diabetes. A notable product is Opdivo (nivolumab), an immuno-oncology medicine developed through a collaboration involving Ono and Medarex, which was later acquired by Bristol Myers Squibb.

The company serves patients in Japan and works with international pharmaceutical partners to develop and commercialize medicines in other markets.

View Ono Pharmaceutical Profile
Earnings Tools